SCHEMBL5568977

SCHEMBL5568977

CNC(=O)c1cc(Oc2cccc(NC(=O)Nc3cc(C)c(Cl)cc3OCCN(C)C)c2)ccn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.57
GSK3B P49841 2/20 0.54
DDR2 Q16832 4/20 0.52
KDR P35968 6/20 0.51
MAPK14 Q16539 4/20 0.49
ABL1 P00519 3/20 0.49
EPHA2 P29317 3/20 0.49
MAP3K20 Q9NYL2 3/20 0.49
PLK4 O00444 2/20 0.49
AURKA O14965 2/20 0.49
MAPK13 O15264 2/20 0.49
MAP4K4 O95819 2/20 0.49
LCK P06239 2/20 0.49
FYN P06241 2/20 0.49
LYN P07948 2/20 0.49
SRC P12931 2/20 0.49
RPS6KB1 P23443 2/20 0.49
AXL P30530 2/20 0.49
FRK P42685 2/20 0.49
MAPK9 P45984 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13648335 0.93 DDR2 (0.51) RETGSK3BDDR2KDRMAPK14
SCHEMBL5570068 0.92 GSK3B (0.64) RETGSK3BDDR2KDRMAPK14
SCHEMBL5564737 0.90 RET (0.58) RETGSK3BDDR2KDRMAPK14
SCHEMBL5570191 0.90 RET (0.58) RETGSK3BDDR2KDRMAPK14
SCHEMBL14453626 0.89 GSK3B (0.69) RETGSK3BDDR2KDRMAPK14
SCHEMBL13603582 0.88 DDR2 (0.64) RETGSK3BDDR2KDRMAPK14
SCHEMBL13648430 0.86 DDR2 (0.52) RETGSK3BDDR2KDRMAPK14
SCHEMBL5565578 0.86 RET (0.54) RETGSK3BDDR2KDRMAPK14
SCHEMBL13648325 0.86 KDR (0.50) RETGSK3BDDR2KDRMAPK14
SCHEMBL171021 0.85 DDR2 (0.65) RETGSK3BDDR2KDRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007519653-A 2007-07-19 JP claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US claimed
EP-1730111-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-12-13 EP claimed
WO-2005075425-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-08-18 WO claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US disclosed
EP-1730111-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-12-13 EP disclosed
WO-2005075425-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161677-A1 Bisarylurea derivatives BRAF, RAF1, NRAS RET 40/4885GSK3B 352/4885DDR2 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.